Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson’s disease

Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson’s disease

Abstract In pursuit of treating Parkinson’s disease with cell replacement therapy, differentiated induced pluripotent stem cells (iPSC) are an ideal source of midbrain dopaminergic (mDA) cells. We previously established a protocol for differentiating iPSC-derived post-mitotic mDA neurons capable of...

Full description

Bibliographic Details
Main Authors: Benjamin M. Hiller, David J. Marmion, Cayla A. Thompson, Nathaniel A. Elliott, Howard Federoff, Patrik Brundin, Virginia B. Mattis, Christopher W. McMahon, Jeffrey H. Kordower
Format: Article
Language:English
Published: Nature Portfolio 2022-04-01
Series:npj Regenerative Medicine
Online Access:https://doi.org/10.1038/s41536-022-00221-y

Internet

https://doi.org/10.1038/s41536-022-00221-y

Similar Items